NASDAQ:RPTX Repare Therapeutics (RPTX) Stock Price, News & Analysis → Exposed: 10 CENT Crypto to Explode April 20th? (From True Market Insiders) (Ad) Free RPTX Stock Alerts $3.36 +0.10 (+3.07%) (As of 04/23/2024 ET) Add Compare Share Share Today's Range$3.24▼$3.4350-Day Range$3.02▼$7.2052-Week Range$2.98▼$13.85Volume175,602 shsAverage Volume146,141 shsMarket Capitalization$124.32 millionP/E RatioN/ADividend YieldN/APrice Target$17.33 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Repare Therapeutics alerts: Email Address Repare Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside415.9% Upside$17.33 Price TargetShort InterestBearish2.39% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.76Based on 5 Articles This WeekInsider TradingSelling Shares$54,037 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($2.74) to ($3.08) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.08 out of 5 starsMedical Sector357th out of 910 stocksPharmaceutical Preparations Industry160th out of 426 stocks 3.5 Analyst's Opinion Consensus RatingRepare Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageRepare Therapeutics has only been the subject of 2 research reports in the past 90 days. Previous Next 2.0 Short Interest Percentage of Shares Shorted2.39% of the float of Repare Therapeutics has been sold short.Short Interest Ratio / Days to CoverRepare Therapeutics has a short interest ratio ("days to cover") of 4.6.Change versus previous monthShort interest in Repare Therapeutics has recently increased by 3.40%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldRepare Therapeutics does not currently pay a dividend.Dividend GrowthRepare Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for RPTX. Previous Next 3.2 News and Social Media Coverage News SentimentRepare Therapeutics has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.45 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Repare Therapeutics this week, compared to 2 articles on an average week.Search InterestOnly 3 people have searched for RPTX on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat Follows5 people have added Repare Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 400% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Repare Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $54,037.00 in company stock.Percentage Held by Insiders28.50% of the stock of Repare Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions85.09% of the stock of Repare Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Repare Therapeutics are expected to decrease in the coming year, from ($2.74) to ($3.08) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Repare Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Repare Therapeutics is -1.51, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioRepare Therapeutics has a P/B Ratio of 0.67. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Market InsidersExposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinClick For My #1 FREE Crypto for 2024 About Repare Therapeutics Stock (NASDAQ:RPTX)Repare Therapeutics Inc., a clinical-stage precision oncology company, engages in the discovery and development of therapeutics by using its synthetic lethality approach in Canada and the United States. It uses its SNIPRx, a proprietary, genome-wide, and CRISPR-enabled platform, to discover, validate, and build a pipeline of SL-based therapeutics that focuses on genomic instability, including DNA damage repair. The company's lead product candidate is Camonsertib (RP-3500), an oral small molecule inhibitor under Phase ½ development for the treatment of solid tumors with specific DNA damage repair-related genomic alterations. It is also developing Lunresertib (RP-6306), a PKMYT1 Inhibitor, which is under Phase 1 clinical trial for tumors with genetic alterations characterized by CCNE1 amplification; RP-1664, an oral PLK4 inhibitor, under Phase 1 clinical trial designed to harness the synthetic lethal relationship with TRIM37 amplification or overexpression in solid tumors; and RP-3467, a polymerase theta adenosinetriphosphatase (ATPase) inhibitor, a SL target associated with BRCA mutations and other genomic alterations. The company has license and collaboration agreement with Hoffmann-La Roche Inc. and F. Hoffmann-La Roche Ltd; Bristol-Myers Squibb Company; New York University; and Ono Pharmaceutical Co., as well as a clinical study and collaboration agreement with Debiopharm to explore the synthetic lethal combination of PKMYT1 and WEE1 inhibition in cancer. Repare Therapeutics Inc. was incorporated in 2016 and is headquartered in Montréal, Canada.Read More RPTX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart RPTX Stock News HeadlinesApril 2, 2024 | insidertrades.comLloyd Mitchell Segal Sells 2,491 Shares of Repare Therapeutics Inc. (NASDAQ:RPTX) StockMarch 28, 2024 | insidertrades.comInsider Selling: Repare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells 2,650 Shares of StockApril 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 28, 2024 | insidertrades.comRepare Therapeutics Inc. (NASDAQ:RPTX) CEO Sells $12,693.50 in StockApril 22, 2024 | markets.businessinsider.comBuy Rating Reaffirmed for Repare Therapeutics on Strong Clinical Outlook and Attractive ValuationApril 21, 2024 | americanbankingnews.comBloom Burton Upgrades Repare Therapeutics (NASDAQ:RPTX) to "Buy"April 20, 2024 | finance.yahoo.comRepare Therapeutics Inc.'s (NASDAQ:RPTX) market cap dropped US$21m last week; Private equity firms bore the bruntMarch 29, 2024 | investing.comRepare therapeutics exec sells shares worth $7,000April 23, 2024 | True Market Insiders (Ad)Exposed: 10 CENT Crypto to Explode April 20th?Former Wall Street Insider and Professional Money Manager Reveals 4 Cryptos BETTER Than BitcoinMarch 16, 2024 | finance.yahoo.comRPTX Apr 2024 7.500 callMarch 16, 2024 | finance.yahoo.comRPTX Jul 2024 7.500 callMarch 15, 2024 | businesswire.comRepare Therapeutics Inc. (RPTX) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Seek Compensation for Alleged WrongdoingsMarch 11, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXMarch 8, 2024 | markets.businessinsider.comBuy Rating Affirmed for Repare Therapeutics: Strong Financials and Promising Clinical Catalysts AheadMarch 3, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXMarch 1, 2024 | finance.yahoo.comRepare Therapeutics Full Year 2023 Earnings: Misses ExpectationsFebruary 29, 2024 | businesswire.comRepare Therapeutics to Participate in Two Upcoming Investor ConferencesFebruary 28, 2024 | msn.comSHAREHOLDER ALERT: Potential Recovery for Repare Therapeutics Inc. (RPTX) InvestorsFebruary 28, 2024 | benzinga.comRecap: Repare Therapeutics Q4 EarningsFebruary 28, 2024 | finance.yahoo.comRepare Therapeutics Inc (RPTX) Reports Financial Outcomes for Q4 and Full Year 2023February 28, 2024 | businesswire.comRepare Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2023 Financial ResultsFebruary 24, 2024 | prnewswire.comSHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims on Behalf of Investors of Repare Therapeutics Inc. - RPTXFebruary 22, 2024 | markets.businessinsider.comStrong Buy: Repare Therapeutics’ Promising Clinical Outcomes in Cancer TherapyFebruary 17, 2024 | finance.yahoo.comWe're Keeping An Eye On Repare Therapeutics' (NASDAQ:RPTX) Cash Burn RateFebruary 17, 2024 | finance.yahoo.comRPTX Mar 2024 7.500 callFebruary 16, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)February 16, 2024 | businesswire.comKirby McInerney LLP Announces Investigation of Shareholder Claims Against Repare Therapeutics Inc. (RPTX)See More Headlines Receive RPTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Repare Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings2/28/2024Today4/23/2024Next Earnings (Estimated)5/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:RPTX CUSIPN/A CIK1808158 Webwww.reparerx.com Phone857-412-7018FaxN/AEmployees179Year Founded2016Price Target and Rating Average Stock Price Target$17.33 High Stock Price Target$25.00 Low Stock Price Target$10.00 Potential Upside/Downside+405.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($2.23) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-93,800,000.00 Net Margins-183.43% Pretax Margin-201.79% Return on Equity-39.82% Return on Assets-31.84% Debt Debt-to-Equity RatioN/A Current Ratio6.24 Quick Ratio6.24 Sales & Book Value Annual Sales$51.13 million Price / Sales2.48 Cash FlowN/A Price / Cash FlowN/A Book Value$5.03 per share Price / Book0.68Miscellaneous Outstanding Shares37,000,000Free Float26,456,000Market Cap$126.91 million OptionableOptionable Beta0.57 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Lloyd Mitchell Segal (Age 60)President, CEO & Director Comp: $913.39kDr. Michael Zinda Ph.D. (Age 53)Executive VP & Chief Scientific Officer Comp: $641.53kDr. Maria Koehler M.D. (Age 67)Ph.D., Executive VP & Chief Medical Officer Comp: $682.8kDr. Daniel Durocher Ph.D.Co-FounderDr. Frank Sicheri Ph.D.Co-FounderDr. Agnel Sfeir Ph.D.Co-FounderMr. Steve Forte (Age 45)Executive VP & CFO Comp: $608.52kMr. Daniel BelangerExecutive Vice President of Human ResourceMr. Cameron BlackExecutive Vice President of DiscoveryDr. Kim A. Seth Ph.D.Executive VP & Chief Business OfficerMore ExecutivesKey CompetitorsNuvectis PharmaNASDAQ:NVCTOptiNoseNASDAQ:OPTNVistagen TherapeuticsNASDAQ:VTGNCytomX TherapeuticsNASDAQ:CTMXEliem TherapeuticsNASDAQ:ELYMView All CompetitorsInsiders & InstitutionsSumitomo Mitsui Trust Holdings Inc.Sold 17,562 shares on 4/19/2024Ownership: 0.834%Lloyd Mitchell SegalSold 2,491 sharesTotal: $11,533.33 ($4.63/share)Michael ZindaSold 410 sharesTotal: $1,910.60 ($4.66/share)Steve ForteSold 789 sharesTotal: $3,637.29 ($4.61/share)Lloyd Mitchell SegalSold 2,650 sharesTotal: $12,269.50 ($4.63/share)View All Insider TransactionsView All Institutional Transactions RPTX Stock Analysis - Frequently Asked Questions Should I buy or sell Repare Therapeutics stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Repare Therapeutics in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" RPTX shares. View RPTX analyst ratings or view top-rated stocks. What is Repare Therapeutics' stock price target for 2024? 4 Wall Street research analysts have issued 12-month price targets for Repare Therapeutics' stock. Their RPTX share price targets range from $10.00 to $25.00. On average, they predict the company's share price to reach $17.33 in the next twelve months. This suggests a possible upside of 415.9% from the stock's current price. View analysts price targets for RPTX or view top-rated stocks among Wall Street analysts. How have RPTX shares performed in 2024? Repare Therapeutics' stock was trading at $7.30 at the beginning of the year. Since then, RPTX stock has decreased by 54.0% and is now trading at $3.36. View the best growth stocks for 2024 here. When is Repare Therapeutics' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024. View our RPTX earnings forecast. How were Repare Therapeutics' earnings last quarter? Repare Therapeutics Inc. (NASDAQ:RPTX) announced its quarterly earnings results on Wednesday, February, 28th. The company reported ($0.67) EPS for the quarter, missing the consensus estimate of ($0.56) by $0.11. The business had revenue of $13.05 million for the quarter, compared to analyst estimates of $15.92 million. Repare Therapeutics had a negative trailing twelve-month return on equity of 39.82% and a negative net margin of 183.43%. What ETF holds Repare Therapeutics' stock? ARK Genomic Revolution ETF holds 2,612,292 shares of RPTX stock, representing 0.68% of its portfolio. What other stocks do shareholders of Repare Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some companies that other Repare Therapeutics investors own include Boeing (BA), Marvell Technology (MRVL), Adobe (ADBE), Albertsons Companies (ACI), Abbott Laboratories (ABT), AES (AES), Autodesk (ADSK) and When did Repare Therapeutics IPO? Repare Therapeutics (RPTX) raised $126 million in an initial public offering (IPO) on Friday, June 19th 2020. The company issued 7,400,000 shares at $16.00-$18.00 per share. Morgan Stanley, Goldman Sachs, Cowen and Piper Sandler acted as the underwriters for the IPO. Who are Repare Therapeutics' major shareholders? Repare Therapeutics' stock is owned by many different institutional and retail investors. Top institutional investors include Sumitomo Mitsui Trust Holdings Inc. (0.83%). Insiders that own company stock include Ansbert Gadicke, Bvf Partners L P/Il, David P Bonita, Davis Jerel, John A Mastalerz Jr, Lloyd Mitchell Segal, Michael Zinda, Orbimed Advisors Llc, Steve Forte, Thomas Civik and Todd Foley. View institutional ownership trends. How do I buy shares of Repare Therapeutics? Shares of RPTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:RPTX) was last updated on 4/23/2024 by MarketBeat.com Staff From Our PartnersSHOCKING Crypto Leak…Crypto 101 MediaDid You Get Your Free Bitcoin Yet?Crypto Swap Profitstop AI stock (it’s not MSFT, GOOGL, AMZN or AAPL)Traders AgencyDon’t Miss Out on the AI Gold Rush That’s Just Getting StartedBanyan Hill PublishingMan Who Predicted 2008: “This Will be Worse.”AltimetryGreat Crypto BullWeiss RatingsThe Next Nvidia?InvestorPlaceExposed: 10 CENT Crypto to Explode April 20th?True Market Insiders Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Repare Therapeutics Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
